In the third quarter, INNOVENT BIO achieved total product revenue exceeding 3.3 billion yuan, maintaining a strong year-on-year growth of approximately 40%
INNOVENT BIO achieved total product revenue exceeding 3.3 billion yuan in the third quarter of 2025, a year-on-year increase of approximately 40%. The company maintains a leading position in the field of cancer treatment, with major products such as DABOSHU® showing steady growth, and the proportion of revenue from innovative products increasing. At the same time, comprehensive product lines such as XINERMEI® and XINBILE® have shown significant market access and marketing effectiveness, driving revenue growth. The company has received approval for 16 products and is committed to global innovation and sustainable growth, aiming to become a world-class biopharmaceutical company
According to the announcement from INNOVENT BIO (01801), in the third quarter of 2025, the company achieved total product revenue exceeding RMB 3.3 billion, maintaining a strong year-on-year growth of approximately 40%. This growth is attributed to the dual drivers of oncology and comprehensive pipelines: 1) The company maintains a leading position in the field of cancer treatment, with significant advantages in its product portfolio. Major products such as Tyvyt® (sintilimab injection) have shown steady growth, and the contribution of innovative product revenue has further increased; 2) The potential of the comprehensive product line is being rapidly released, contributing new growth drivers: The market access and channel marketing efforts for IBI308® (masitinib injection), IBI101® (toripalimab injection), and IBI110® (tremelimumab N01 injection) have been significant, with accelerated product volume and a substantial increase in revenue contribution. The second diabetes indication for masitinib has also been approved for market launch by the National Medical Products Administration of China, further providing high-quality and accessible innovative treatment solutions for a broader patient population.
In addition, the company is committed to two core strategies of sustainable growth and global innovation, laying out a rich pipeline in oncology and comprehensive product lines (cardiovascular and metabolism, autoimmune, ophthalmology). To date, the company has obtained approvals for 16 products, with 2 varieties under review by the National Medical Products Administration of China, 4 new drug molecules entering Phase 3 or pivotal clinical studies, and approximately 15 new drug varieties having entered clinical research. The year 2025 is a significant year for the company as it enters a new period of dual-driven and global innovative development, steadily moving towards the vision of "becoming a world-class biopharmaceutical company."
